BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 11888936)

  • 21. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
    Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R
    Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW; Neckers LM
    Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
    da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
    Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
    Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
    Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
    Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q; Nishiuchi R; Kitamura T; Kersey JH
    Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
    Bai RY; Dieter P; Peschel C; Morris SW; Duyster J
    Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation.
    Sasaki K; Sugaya M; Fujita H; Takeuchi K; Torii H; Asahina A; Tamaki K
    Br J Dermatol; 2004 Jun; 150(6):1202-7. PubMed ID: 15214912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
    Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
    Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
    Terry J; Lubieniecka JM; Kwan W; Liu S; Nielsen TO
    Clin Cancer Res; 2005 Aug; 11(15):5631-8. PubMed ID: 16061882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
    Galkin AV; Melnick JS; Kim S; Hood TL; Li N; Li L; Xia G; Steensma R; Chopiuk G; Jiang J; Wan Y; Ding P; Liu Y; Sun F; Schultz PG; Gray NS; Warmuth M
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):270-5. PubMed ID: 17185414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
    Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B
    Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.
    Bai RY; Ouyang T; Miething C; Morris SW; Peschel C; Duyster J
    Blood; 2000 Dec; 96(13):4319-27. PubMed ID: 11110708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
    Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
    Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
    Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
    Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.